Engineered NK Cells Containing Deleted TGF-BetaR2 and NR3C1 for the Treatment of Recurrent Grade 4 Recurrent Astrocytoma

Inclusion Criteria

• DOSE ESCALATION (GROUP 1)
• Signed and dated informed consent
• Male or female subjects aged >= 12 years on the day of signing informed consent
• Has histologically confirmed supratentorial World Health Organization grade 4 recurrent astrocytoma to include recurrent glioblastoma (IDH-wildtype grade 4 astrocytoma) recurrent IDH-mutant WHO grade 4 astrocytoma, and recurrent gliosarcoma with any prior number of recurrences, and who have received prior radiation and temozolomide therapy. Participants will be eligible if the original histology was lower-grade glioma and a subsequent histological diagnosis of recurrent glioblastoma or variants is made
• Karnofsky performance status (KPS) of >= 70 at trial entry. Lansky >= 70 at trial entry for patients less than 16.
• Must be at least 12 weeks from receiving conformal radiation, unless RANO criteria for early progression are met
• A baseline brain MRI ABTI must be obtained no more than 30 days prior to study registration
• Patients having undergone recent surgery are eligible as long as they are at least 3 weeks from resection or at least 1 week from stereotactic biopsy and recovered from any operative or perioperative complications. Patients with non-measurable tumor after resection will NOT be excluded; if they do not experience tumor progression while on trial, response will be labeled as “stable disease” (and not as “complete response”)
• White blood cell (WBC) count >= 3 x 10^9/L
• Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
• Lymphocyte count >= 0.5 x 10^9/L
• Platelet count >= 120 x 10^9/L
• Hemoglobin (Hgb) >= 9 g/dL (in absence of blood transfusion)
• Total bilirubin level =< 1.5 x upper limit of normal (ULN)
• Aspartate aminotransferase (AST) level =< 2.5 x ULN
• Alanine aminotransferase (ALT) level =< 2.5 x ULN
• International normalized ratio (INR) =< 1.5
• Adequate renal function defined by creatinine =< 1.5 X upper limit of normal (ULN) OR creatinine clearance >= 60 mL/min for subject with creatinine levels > 1.5 X institutional ULN
• Female subject of childbearing potential should have a negative serum pregnancy test within 14 days of study registration
• Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study and for 3 months after the last dose of study therapy. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year
• Male subjects should agree to use 2 methods of highly effective contraception starting with the first dose of study therapy and for 3 months after the last dose of study therapy
• SURGICAL EXPANSION GROUP (GROUP 2)
• Have evaluable or measurable disease of >= 1 cm^2 of contrast enhancing disease at a surgically accessible site at baseline
• Have a tumor that is judged to be surgically resectable by the treating neurosurgeon

Exclusion Criteria

• Has been treated previously with bevacizumab or Gliadel® wafers
• Has received prior interstitial brachytherapy, implanted chemotherapy, or therapeutics delivered by local injection or convection enhanced delivery
• Is currently participating in or has participated in a study of a cancer directed investigational agent or using an investigational device 4 weeks since last dose of agent administration, or is planning to continue or start treatment with Optune® during participation in this trial
• Has known severe hypersensitivity reactions to monoclonal antibodies (grade >= 3 National Cancer Institute [NCI]-Common Terminology Criteria for Adverse Events [CTCAE] version [v]5), any history of anaphylaxis, or recent, within 5 months, history of uncontrolled asthma
• Has a known history of human immunodeficiency virus (HIV) (positive HIV 1/2 antibodies); human T-cell lymphotropic virus (HTLV)1 and/or HTLV2; active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected). Patients with prior hepatitis B virus (HBV) vaccination (anti-hepatitis B surface antibody [HBs] positive, HBsAg negative, anti-hepatitis B core antibody [HBc] negative) will NOT be excluded
• Has a diagnosis of immunodeficiency or is receiving any immunosuppressive therapy within 7 days prior to study registration
• Has had prior chemotherapy or targeted small molecule therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent * Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study * Note: If subject received major surgery (other than craniotomy), they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
• Has had prior radiation therapy less than 12 weeks prior to enrollment; unless RANO criteria for early progression are met
• Has had prior therapy with any antibody/drug targeting T cell co-regulatory proteins (immune checkpoints) such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody
• Has a known additional malignancy that is progressing or requires active treatment. Exceptions include superficial tumors considered adequately treated locally with curative intent, including but not limited to basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy. Any exceptions must be discussed with the protocol principal investigator (PI)
• Has known gliomatous meningitis or extracranial disease, or tumor localized primarily to the brainstem or spinal cord
• Midline shift greater than 0.5 cm or pending herniation
• Tumors no larger than 5 cm in its greatest diameter
• Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjogren’s syndrome will not be excluded from the study
• Has evidence of interstitial lung disease or active, non-infectious pneumonitis
• Has an active infection requiring systemic therapy or that in the opinion of the PI may interfere with the subject’s participation, assessment of experimental treatment toxicity or increase the subject’s risk of side effects
• Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate in the opinion of the treating investigator
• Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
• Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit and through 3 months after last dose of the study treatment
• Has received a live vaccine within 30 days prior to the first dose of trial treatment
• Has a contraindication for undergoing MRIs
• Has evidence of bleeding diathesis or coagulopathy
• Is on full dose anticoagulation or antiplatelet therapy
• Has significant hemorrhage on baseline scan defined as > 1 cm diameter of acute blood
• Has received any organ transplantation, including allogeneic stem-cell transplantation, but with the exception of transplants that do not require immunosuppression (e.g., corneal transplant, hair transplant)
• Has multifocal disease. Subject has multifocal GBM, defined as discrete sites of contrast enhancing disease without contiguous T2/FLAIR abnormality that require distinct radiotherapy ports. Satellite lesions that are associated with a contiguous area of T2/FLAIR abnormality as the main lesion(s) and that are encompassed within the same radiotherapy port as the main lesion(s) are permitted